CATX
Perspective·AMEX
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Signals Analysis
Bullish signal 3
Bearish signal 3
Consensus Rating "Strong Buy"
Ample Liquidity
High Gross Profit Margin
Significant Revenue Decline
Significant Net Income Decline
EPS Below Expectations
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About CATX
Perspective Therapeutics, Inc.
A company that is innovative and forward-looking in the field of radiopharmaceutical treatment for cancer.
Healthcare Equipment and Supplies
--
04/19/2007
American Stock Exchange
138
12-31
Common stock
2401 Elliott Avenue, Suite 320, Seattle, Washington 98121
--
Perspective Therapeutics, Inc., was founded in Delaware. The company is a medical technology and radiopharmaceutical company that has pioneered advanced therapeutic applications for systemic cancers. The company is the sole producer of Cesium-131 brachytherapy seeds and has a proprietary technology that utilizes the isotope lead -212 to deliver powerful α-radiation to cancer cells through specialized targeted peptides. The company is also developing complementary imaging diagnostic technologies that combine the same targeted peptides to provide opportunities for personalized therapy and optimized patient outcomes. This "therapeutic diagnosis" approach enables people to see specific tumors and then treat them, potentially improving efficacy and minimizing toxicity associated with many other types of cancer treatment. The company's melanoma (VMT01) and neuroendocrine tumor (VMT-a-NET) programs are entering phase 1/2 a imaging and therapeutic trials for the treatment of metastatic melanoma and neuroendocrine tumors at several leading academic institutions. The company has also developed a proprietary lead-212 generator to ensure isotope availability for clinical trials and commercial operations.
Company Financials
EPS
CATX has released its 2025 Q3 earnings. EPS was reported at -0.35, versus the expected -0.32, missing expectations. The chart below visualizes how CATX has performed over recent quarters, highlighting trends in earnings surprises.
Revenue & Expenses
CATX has released its 2025 Q3 earnings report, with revenue of 209.00K, reflecting a YoY change of -43.36%, and net profit of -25.97M, showing a YoY change of -71.73%. The Sankey diagram below clearly presents CATX's revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
